3
ICAP

ICAP’s Elaine Abrams, MD, senior research director, was featured in a Nov 30 article in The New York Times, which reported that for the 80,000 children who die of H.I.V. each year, drugs are often bitter or hard to swallow. Dolutegravir will soon come in a tasty dissolving tablet. Children are hard to treat because many H.I.V. medicines taste bitter, come in pills that infants cannot swallow or are alcohol-based syrups that need refrigeration. Dr. Abrams says:

“This is truly an advance. The products currently available for pediatric treatment are less than optimal. There have been a few new formulations, but they haven’t been as successful as anticipated.”

Read the full article in The New York Times


A major global health organization that has been improving public health in countries around the world for over 15 years, ICAP works to transform the health of populations through innovation, science, and global collaboration. Based at Columbia University in New York City, where it is part of the Mailman School of Public Health, ICAP has projects in more than 30 countries, working side-by-side with ministries of health and local partners to confront some of the world’s toughest health challenges. Through meaningful research, tailored technical assistance, effective training and education programs, and rigorous surveillance to measure and evaluate the impact of public health interventions, ICAP aims to realize a global vision of healthy people, empowered communities, and thriving societies. Online at icap.columbia.edu

Related Items